Skip to main content
SpringerLink
Log in

Brentuximab-vedotin/cisplatin/cytarabine/dexamethasone

Haematological toxicity during off-label use: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Muggeo P, et al. BV-DHAP as salvage treatment for high risk adolescent Hodgkin lymphoma. Klinische Padiatrie 232 (Suppl.): 106-107, No. 2, 2020. Available from: URL: http://doi.org/10.1055/s-0040-1701898 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brentuximab-vedotin/cisplatin/cytarabine/dexamethasone. Reactions Weekly 1807, 46 (2020). https://doi.org/10.1007/s40278-020-79332-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-79332-2

Search

Navigation